

**Quality-Data Code Submission Error Report  
First Quarter 2011 Physician Quality Reporting System**

**Report Date: 06/23/2011**

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

**Column Definitions:**

**QDC Submission Attempts:**

- Total QDCs Reported - The number of instances where a TIN/NPI submitted a QDC for that measure.
- Total Valid QDCs Reported on Eligible Cases - The number of instances where a TIN/NPI submitted a valid QDC for that measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported on Eligible Cases.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator requirements.

**Denominator Mismatch:**

- Measure Reported with Incorrect Age and/or Gender - The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.
- Incorrect Diagnosis and/or HCPCS - The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
- Measure Reported on an Instance with a Missing CPT Code - The number of occurrences of QDC reporting when there are no CPT codes for billable services on the claim associated with the denominator requirements for the measure.

**How to Read the Quality-Data Code Submission Error Report by Measure:**

Using Measure #1-Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus as an example, we find the following information as we read across each column:

191,707 QDC submissions were received for this measure, 149,749 of which were considered valid. Therefore, the Valid Submission Rate is 78.11%. There were a total of 150,040 QDCs reported on eligible cases. The rest of the columns explain reasons for invalid submissions for measure #1. We see that 33,953 (17.71%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 39,328 (20.51%) submissions were for patient encounters and/or diagnoses that are not listed in the denominator; 717 (0.37%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, TIN/NPI.

## **Analysis Findings Include:**

### **Quality Data Code Submission Error Report by Individual Measure (Claims)**

1. The top 5 measures with the highest percentage of valid QDCs codes submitted were:

- #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (98.14%)
- #177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity (97.48%)
- #147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.34%)
- #158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy (97.07%)
- #225 Radiology: Reminder System for Mammograms (96.92%)

2. The 5 measures with the lowest percentage of Valid QDCs submitted (with at least 1 eligible instance) were:

- #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (0.26%)
- #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (0.58%)
- #189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days (6.67%)
- #122 Chronic Kidney Disease (CKD): Blood Pressure Management (15.74%)
- #46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility (16.33%)

3. The 5 measures with the highest rate of HCPCS/diagnosis errors were:

- #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (99.61%)
- #66 Appropriate Testing for Children with Pharyngitis (95.18%)
- #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (95.03%)
- #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (92.85%)
- #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (90.73%)

4. The 5 measures with the highest rate of patient age/gender errors were:

- #66 Appropriate Testing for Children with Pharyngitis (100.00%)
- #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (100.00%)
- #94 Otitis Media with Effusion (OME): Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility (100.00%)
- #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (94.93%)
- #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (87.10%)

## Physician Quality Reporting - Quality-Data Code Submission Error Report by Individual Measure (Claims)

Report Includes Claims Data for Services Provided from January 1, 2011 through March 25, 2011 and Processed by March 25, 2011.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	191,707	149,749	78.11%	150,040	33,953	17.71%	39,328	20.51%	717	0.37%
#2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	175,993	138,039	78.43%	138,384	29,654	16.85%	35,677	20.27%	657	0.37%
#3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	196,042	140,083	71.46%	144,267	36,684	18.71%	49,227	25.11%	783	0.40%
#6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	234,817	214,942	91.54%	214,942	0	0.00%	19,169	8.16%	637	0.27%
#9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	6,496	4,895	75.35%	4,895	0	0.00%	1,506	23.18%	74	1.14%
#10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	95,226	78,625	82.57%	84,342	0	0.00%	9,797	10.29%	594	0.62%
#12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	356,862	299,813	84.01%	300,023	0	0.00%	56,085	15.72%	572	0.16%
#14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	330,711	317,396	95.97%	317,534	325	0.10%	12,443	3.76%	674	0.20%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	96,337	80,642	83.71%	80,664	0	0.00%	15,377	15.96%	242	0.25%
#19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	67,688	40,511	59.85%	50,893	0	0.00%	16,591	24.51%	155	0.23%
#20 Perioperative Care: Timing of Antibiotic Prophylaxis <input type="checkbox"/> Ordering Physician	24,631	18,760	76.16%	18,760	4	0.02%	5,717	23.21%	154	0.63%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#21 Perioperative Care: Selection of Prophylactic Antibiotic <input type="checkbox"/> First OR Second Generation Cephalosporin	46,236	36,264	78.43%	36,264	6	0.01%	9,624	20.81%	348	0.75%
#22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	44,269	23,802	53.77%	31,108	8	0.02%	12,770	28.85%	391	0.88%
#23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	37,808	29,672	78.48%	29,672	2	0.01%	7,891	20.87%	245	0.65%
#24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	2,917	668	22.90%	668	15	0.51%	1,939	66.47%	61	2.09%
#28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	13,266	12,542	94.54%	12,542	0	0.00%	683	5.15%	24	0.18%
#30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	759,851	611,971	80.54%	614,347	42	0.01%	141,486	18.62%	4,018	0.53%
#31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	3,506	2,804	79.98%	2,804	0	0.00%	676	19.28%	22	0.63%
#32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	4,651	3,997	85.94%	3,997	0	0.00%	604	12.99%	45	0.97%
#35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	2,248	1,543	68.64%	1,745	0	0.00%	492	21.89%	8	0.36%
#36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	3,505	2,888	82.40%	2,897	0	0.00%	578	16.49%	25	0.71%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	131,526	120,793	91.84%	120,793	6,474	4.92%	9,488	7.21%	1,245	0.95%
#40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	7,943	2,309	29.07%	2,309	89	1.12%	5,306	66.80%	66	0.83%
#41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	19,711	15,321	77.73%	15,321	136	0.69%	4,163	21.12%	169	0.86%
#43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	5,418	3,663	67.61%	3,665	0	0.00%	1,718	31.71%	35	0.65%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORD I demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	3,716	2,491	67.03%	2,491	0	0.00%	1,183	31.84%	42	1.13%
#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	40,124	8,904	22.19%	11,214	6	0.01%	28,385	70.74%	525	1.31%
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	6,797	1,110	16.33%	1,983	265	3.90%	737	10.84%	231	3.40%
#47 Advance Care Plan	230,626	205,868	89.26%	210,473	10,873	4.71%	18,947	8.22%	1,206	0.52%
#48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	85,437	75,596	88.48%	75,597	5,059	5.92%	8,715	10.20%	1,125	1.32%
#49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	19,352	14,335	74.08%	14,336	850	4.39%	4,903	25.34%	53	0.27%
#50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	17,871	13,628	76.26%	13,628	748	4.19%	4,111	23.00%	80	0.45%
#51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	31,456	28,442	90.42%	28,442	0	0.00%	2,897	9.21%	98	0.31%
#52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	26,508	20,184	76.14%	24,394	0	0.00%	1,977	7.46%	129	0.49%
#53 Asthma: Pharmacologic Therapy	2,076	393	18.93%	444	1,585	76.35%	1,381	66.52%	1	0.05%
#54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	294,740	213,918	72.58%	213,925	3,509	1.19%	79,916	27.11%	653	0.22%
#55 12-Lead Electrocardiogram (ECG) Performed for Syncope	293,082	63,357	21.62%	63,357	51,992	17.74%	228,660	78.02%	181	0.06%
#56 Community-Acquired Pneumonia (CAP): Vital Signs	119,807	88,798	74.12%	88,805	3	0.00%	7,964	6.65%	525	0.44%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	129,155	98,540	76.30%	98,540	3	0.00%	6,301	4.88%	530	0.41%
#58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	117,226	90,035	76.80%	90,043	3	0.00%	4,445	3.79%	474	0.40%
#59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	83,450	63,476	76.06%	63,476	2	0.00%	3,233	3.87%	401	0.48%
#64 Asthma: Asthma Assessment	1,394	247	17.72%	247	1,124	80.63%	938	67.29%	1	0.07%
#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	302	0	0.00%	0	302	100.00%	287	95.03%	0	0.00%
#66 Appropriate Testing for Children with Pharyngitis	311	0	0.00%	0	311	100.00%	296	95.18%	0	0.00%
#67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	6,332	5,927	93.60%	5,927	0	0.00%	388	6.13%	16	0.25%
#68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	4,040	3,640	90.10%	3,782	0	0.00%	240	5.94%	15	0.37%
#69 Multiple Myeloma: Treatment with Bisphosphonates	5,368	5,108	95.16%	5,108	0	0.00%	246	4.58%	6	0.11%
#70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	5,523	5,228	94.66%	5,228	0	0.00%	277	5.02%	18	0.33%
#71 Breast Cancer: Hormonal Therapy for Stage IC-IIIc Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	23,551	21,205	90.04%	22,641	70	0.30%	858	3.64%	47	0.20%
#72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	7,200	6,383	88.65%	6,774	0	0.00%	412	5.72%	13	0.18%
#76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	52,955	47,200	89.13%	47,200	0	0.00%	5,247	9.91%	508	0.96%
#79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	4,318	3,949	91.45%	3,949	0	0.00%	299	6.92%	5	0.12%
#84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	855	757	88.54%	772	0	0.00%	79	9.24%	4	0.47%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDl demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#85 Hepatitis C: HCV Genotype Testing Prior to Treatment	840	736	87.62%	778	0	0.00%	60	7.14%	2	0.24%
#86 Hepatitis C: Antiviral Treatment Prescribed	488	437	89.55%	437	0	0.00%	50	10.25%	1	0.20%
#87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	443	382	86.23%	390	0	0.00%	53	11.96%	0	0.00%
#89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	786	664	84.48%	665	0	0.00%	121	15.39%	0	0.00%
#90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	123	76	61.79%	85	0	0.00%	38	30.89%	0	0.00%
#91 Acute Otitis Externa (AOE): Topical Therapy	1,122	1,030	91.80%	1,030	0	0.00%	79	7.04%	13	1.16%
#92 Acute Otitis Externa (AOE): Pain Assessment	1,479	1,161	78.50%	1,161	0	0.00%	292	19.74%	16	1.08%
#93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy <input type="checkbox"/> Avoidance of Inappropriate Use	891	840	94.28%	841	0	0.00%	41	4.60%	9	1.01%
#94 Otitis Media with Effusion (OME): Diagnostic Evaluation <input type="checkbox"/> Assessment of Tympanic Membrane Mobility	120	0	0.00%	0	120	100.00%	86	71.67%	0	0.00%
#99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	10,352	5,691	54.97%	5,692	0	0.00%	4,549	43.94%	52	0.50%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	9,924	3,303	33.28%	3,303	0	0.00%	6,430	64.79%	45	0.45%
#102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	1,379	753	54.60%	790	0	0.00%	569	41.26%	18	1.31%
#104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	1,007	740	73.49%	764	0	0.00%	206	20.46%	37	3.67%
#105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	1,236	892	72.17%	915	0	0.00%	280	22.65%	37	2.99%
#106 Major Depressive Disorder (MDD): Diagnostic Evaluation	4,499	2,852	63.39%	2,852	0	0.00%	1,626	36.14%	13	0.29%
#107 Major Depressive Disorder (MDD): Suicide Risk Assessment	8,719	5,515	63.25%	5,515	0	0.00%	3,173	36.39%	17	0.19%
#108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	13,413	12,892	96.12%	12,899	0	0.00%	479	3.57%	32	0.24%
#109 Osteoarthritis (OA): Function and Pain Assessment	19,654	16,068	81.75%	16,070	0	0.00%	3,152	16.04%	377	1.92%
#110 Preventive Care and Screening: Influenza Immunization for Patients = 50 Years Old	254,393	242,925	95.49%	242,925	3,840	1.51%	9,960	3.92%	1,508	0.59%
#111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	276,147	257,792	93.35%	257,899	9,088	3.29%	16,227	5.88%	2,021	0.73%
#112 Preventive Care and Screening: Screening Mammography	61,729	42,742	69.24%	42,764	16,167	26.19%	16,368	26.52%	2,597	4.21%
#113 Preventive Care and Screening: Colorectal Cancer Screening	154,825	121,184	78.27%	121,262	28,304	18.28%	30,639	19.79%	2,924	1.89%
#116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	303	71	23.43%	71	204	67.33%	222	73.27%	8	2.64%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	188,303	120,722	64.11%	121,132	61,593	32.71%	64,137	34.06%	366	0.19%
#119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	34,387	26,791	77.91%	26,798	6,331	18.41%	6,670	19.40%	218	0.63%
#121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	6,876	3,847	55.95%	3,847	0	0.00%	3,004	43.69%	17	0.25%
#122 Chronic Kidney Disease (CKD): Blood Pressure Management	33,599	5,287	15.74%	5,864	1	0.00%	27,513	81.89%	31	0.09%
#123 Chronic Kidney Disease (CKD): Plan of Care <input type="checkbox"/> Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	8,490	3,591	42.30%	4,066	1	0.01%	4,404	51.87%	7	0.08%
#124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR) Care, Peripheral Neuropathy <input type="checkbox"/> Neurological Evaluation	2,656,830	2,517,948	94.77%	2,517,948	0	0.00%	123,080	4.63%	15,802	0.59%
#127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention <input type="checkbox"/> Evaluation of Footwear	47,090	41,301	87.71%	41,301	0	0.00%	5,529	11.74%	245	0.52%
#128 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention <input type="checkbox"/> Evaluation of Footwear	35,489	32,606	91.88%	32,606	0	0.00%	2,635	7.42%	229	0.65%
#128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	213,153	202,198	94.86%	202,198	1	0.00%	9,041	4.24%	1,914	0.90%
#130 Documentation of Current Medications in the Medical Record	1,227,377	1,170,296	95.35%	1,170,296	4	0.00%	49,407	4.03%	7,674	0.63%
#131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	108,195	81,280	75.12%	81,280	0	0.00%	24,281	22.44%	2,634	2.43%
#134 Screening for Clinical Depression and Follow-Up Plan	6,399	4,433	69.28%	4,433	0	0.00%	1,768	27.63%	198	3.09%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	1,427	824	57.74%	824	0	0.00%	594	41.63%	0	0.00%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	217,628	209,803	96.40%	210,722	177	0.08%	6,483	2.98%	398	0.18%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	89,326	76,360	85.48%	81,356	0	0.00%	7,755	8.68%	193	0.22%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	26,272	17,489	66.57%	17,492	0	0.00%	8,558	32.57%	198	0.75%
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	170,555	158,949	93.20%	158,965	0	0.00%	9,940	5.83%	1,650	0.97%
#146 Radiology: Inappropriate Use of <input type="checkbox"/> Probably Benign <input type="checkbox"/> Assessment Category in Mammography Screening	363,291	349,267	96.14%	350,822	0	0.00%	10,133	2.79%	2,173	0.60%
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	35,090	34,155	97.34%	34,157	0	0.00%	730	2.08%	203	0.58%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	4,399	2,757	62.67%	2,757	0	0.00%	1,627	36.99%	7	0.16%
#154 Falls: Risk Assessment	118,154	89,902	76.09%	104,444	9,653	8.17%	12,353	10.45%	1,357	1.15%
#155 Falls: Plan of Care	22,990	11,937	51.92%	11,938	0	0.00%	0	0.00%	816	3.55%
#156 Oncology: Radiation Dose Limits to Normal Tissues	411	331	80.54%	331	0	0.00%	72	17.52%	4	0.97%
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	142	90	63.38%	90	0	0.00%	52	36.62%	0	0.00%
#158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	852	827	97.07%	827	0	0.00%	21	2.46%	4	0.47%
#163 Diabetes Mellitus: Foot Exam	45,574	29,418	64.55%	29,420	12,518	27.47%	14,513	31.84%	316	0.69%
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	803	723	90.04%	723	0	0.00%	67	8.34%	13	1.62%
#173 Preventive Care and Screening: Unhealthy Alcohol Use <input type="checkbox"/> Screening	120,820	116,481	96.41%	116,481	0	0.00%	3,676	3.04%	663	0.55%
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	0	0	0.00%	0	0	0.00%	0	0.00%	0	0.00%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	4,970	4,390	88.33%	4,827	0	0.00%	130	2.62%	10	0.20%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	5,154	5,024	97.48%	5,024	0	0.00%	116	2.25%	11	0.21%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	5,876	5,587	95.08%	5,587	0	0.00%	269	4.58%	10	0.17%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	3,443	3,379	98.14%	3,383	0	0.00%	58	1.68%	2	0.06%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	3,534	3,389	95.90%	3,463	0	0.00%	64	1.81%	7	0.20%
#181 Elder Maltreatment Screen and Follow-Up Plan	759	305	40.18%	305	31	4.08%	441	58.10%	13	1.71%
#182 Functional Outcome Assessment in Chiropractic Care	30,008	28,416	94.69%	28,416	0	0.00%	1,431	4.77%	161	0.54%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	475	446	93.89%	446	0	0.00%	29	6.11%	0	0.00%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	447	423	94.63%	423	0	0.00%	24	5.37%	0	0.00%
Colonoscopy Interval for Patients with a History of Adenomatous Polyps □ Avoidance of Inappropriate Use	8,124	6,935	85.36%	6,935	0	0.00%	1,105	13.60%	33	0.41%
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	933	531	56.91%	531	0	0.00%	371	39.76%	2	0.21%
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	519	0	0.00%	0	0	0.00%	517	99.61%	0	0.00%

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORD I demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch <sup>c</sup>					
					Measure Reported with Incorrect Age and/or Gender <sup>d</sup>		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
	Total QDCs Reported <sup>a</sup>	Total Valid QDCs Reported on Eligible Cases <sup>b</sup>	% Valid	Total QDCs Reported on Eligible Cases	#	%	#	%	#	%
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	195	13	6.67%	14	0	0.00%	176	90.26%	1	0.51%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	501	435	86.83%	439	0	0.00%	59	11.78%	2	0.40%
#193 Perioperative Temperature Management	442,901	412,725	93.19%	424,657	0	0.00%	16,118	3.64%	2,126	0.48%
#194 Oncology: Cancer Stage Documented	26,186	23,981	91.58%	23,989	0	0.00%	2,079	7.94%	105	0.40%
#195 Radiology: Stenosis Measurement in Carotid Imaging Studies	103,877	96,351	92.75%	96,479	0	0.00%	6,699	6.45%	699	0.67%
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	52,665	44,223	83.97%	46,708	0	0.00%	5,744	10.91%	201	0.38%
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	50,161	46,637	92.97%	46,637	0	0.00%	3,378	6.73%	132	0.26%
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	35,566	32,552	91.53%	32,552	0	0.00%	2,899	8.15%	109	0.31%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	52,363	48,226	92.10%	48,226	0	0.00%	3,961	7.56%	164	0.31%
#225 Radiology: Reminder System for Mammograms	147,450	142,905	96.92%	142,905	165	0.11%	3,671	2.49%	766	0.52%
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	610,360	588,767	96.46%	588,988	3	0.00%	18,726	3.07%	2,646	0.43%
#231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting	6,372	37	0.58%	37	6,049	94.93%	5,781	90.73%	1	0.02%
#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	14,405	37	0.26%	108	12,547	87.10%	13,375	92.85%	1	0.01%
#235 Hypertension (HTN): Plan of Care	9,478	6,605	69.69%	8,409	0	0.00%	991	10.46%	69	0.73%
<b>Total</b>	<b>12,697,453</b>	<b>10,971,089</b>	<b>86.40%</b>	<b>11,057,366</b>	<b>350,894</b>	<b>2.76%</b>	<b>1,452,612</b>	<b>11.44%</b>	<b>73,176</b>	<b>0.58%</b>

<sup>a</sup> The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

<sup>b</sup> The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

<sup>c</sup> The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

<sup>d</sup> The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.